We first consider a specific application for the aggregate utility approach that incorporates panel germline testing for ATM, BRCA1, BRCA2, CHEK2, and PALB2 as part of risk assessment for female breast cancer, for hypothetical screening of a woman without a previous breast cancer diagnosis or breast cancer family history. This evidence concerns the gene BRCA1 and breast cancer.